AI
Aspreva Pharmaceuticals Q3 Profit Declines
Aspreva Pharmaceuticals Corp. (ASPV, ASV.TO) announced that its third quarter net income was $23.3 million or $0.65 per share, compared to net income of $25.4 million or $0.71 per share in the third quarter 2006. Net income for the quarter was impacted by a previously announced one-time $20 million payment to Roche.
Research and Development expenses in the third quarter 2007 were $8.9 million, compared to $12.4 million in the third quarter 2006. Marketing, General and Administrative expenses in the third quarter 2007 were $11.2 million, compared to $10.0 million in the third quarter 2006.
Royalty revenues for the quarter were $62.3 million, up from $47.94 million in the prior year quarter.
Analysts polled by First Call/Thomson Financial expected the company to report earnings of $1.08 per share on revenues of $62.17 million in the third quarter.
http://www.tradingmarkets.com/.site/news/BREAKING%20NEWS/769319/
Aspreva Pharmaceuticals Corp. (ASPV, ASV.TO) announced that its third quarter net income was $23.3 million or $0.65 per share, compared to net income of $25.4 million or $0.71 per share in the third quarter 2006. Net income for the quarter was impacted by a previously announced one-time $20 million payment to Roche.
Research and Development expenses in the third quarter 2007 were $8.9 million, compared to $12.4 million in the third quarter 2006. Marketing, General and Administrative expenses in the third quarter 2007 were $11.2 million, compared to $10.0 million in the third quarter 2006.
Royalty revenues for the quarter were $62.3 million, up from $47.94 million in the prior year quarter.
Analysts polled by First Call/Thomson Financial expected the company to report earnings of $1.08 per share on revenues of $62.17 million in the third quarter.
http://www.tradingmarkets.com/.site/news/BREAKING%20NEWS/769319/
Discover What Traders Are Watching
Explore small cap ideas before they hit the headlines.
